SEC Form 4 · accession 0001209191-15-029054
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Peist
Officer — VP, Legal & IP
Period of report
Mar 20, 2015
Accepted (ET)
Mar 24, 2015 · 9:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Mar 20, 2015 | M | 10,000 | $11.516 | A | 60,000 | D | |
| Common stockF3 | Mar 20, 2015 | S | 10,000 | $11.516 | D | 50,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $3.53 | Mar 20, 2015 | M | 2,500 | D | Jan 28, 2014 | Jan 28, 2023 | Common Stock | 2,500 | 18,647 | D |
| Stock Options (right to buy) | $2.52 | Mar 20, 2015 | M | 2,500 | D | Jun 18, 2014 | Jun 18, 2023 | Common stock | 2,500 | 22,292 | D |
| Stock Options (right to buy) | $2.45 | Mar 20, 2015 | M | 5,000 | D | Jan 3, 2015 | Jan 3, 2024 | Common stock | 5,000 | 45,000 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.17 to $11.95. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.17 to $11.95. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.